Is the mGlu5 receptor a possible target for new antidepressant drugs?

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1506-1511

  Palucha Poniewiera, Agnieszka ^a   Wieroñska, Joanna M ^a   Brañski, Piotr ^a   Burnat, Grzegorz ^a   Chruoecicka, Barbara ^a   Pilc, Andrzej ^a,b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antidepressant drugs; Ketamine; MGlu5 receptor; MPEP; MTEP; NMDA receptor

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; ANTIDEPRESSANT AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; UNCLASSIFIED DRUG;

ANTIDEPRESSANT ACTIVITY; DEPRESSION; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL ANIMAL; HUMAN; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; HUMANS; RECEPTOR, METABOTROPIC GLUTAMATE 5;

EID: 84894131906     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/s1734-1140(13)71511-1     Document Type: Article

References (40)

1. Aan Het Rot M, Zarate CA Jr., Charney DS, Mathew SJ: Ketamine for depression: where do we go from here? Biol Psychiatry, 2012, 72, 537-547.
2. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ: Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci, 2000, 20, 7871-7879.
3. Belozertseva IV, Kos T, Popik P, Danysz W, Bespalov AY: Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests. Eur Neuropsychopharmacol, 2007, 17, 172-179. (Pubitemid 44779190)
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JA: Antidepressant effects of ketamine in depressed patients. Biol Psychiatry, 2000, 47, 351-354. (Pubitemid 30109248)
5. Boothby LA, Doering PL: Acamprosate for the treatment of alcohol dependence. Clin Ther, 2005, 27, 695-714. (Pubitemid 41583518)
6. Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Schaffhauser H, Rao SP, Varney MA, Anderson JJ: Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: interaction with serotonergic systems. Neuropharmacology, 2003, 44, 562-572. (Pubitemid 36369137)
7. Conn PJ, Pin JP: Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol, 1997, 37, 205-237. (Pubitemid 27238875)
8. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L et al.: 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem, 2003, 46, 204-206. (Pubitemid 36078139)
9. Cowen MS, Djouma E, Lawrence AJ: The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3- thiazol-4-yl)ethynyl]-pyridine reduces ethanol selfadministration in multiple strains of alcohol-preferring rats and regulates olfactory glutamatergic systems. J Pharmacol Exp Ther, 2005, 315, 590-600. (Pubitemid 41500723)
10. Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C et al.: Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study. Am J Psychiatry, 2011, 168, 727-734.
11. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA et al.: A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry, 2010, 67, 793-802.
12. Doherty AJ, Palmer MJ, Bortolotto ZA, Hargreaves A, Kingston AE, Ornstein PL, Schoepp DD et al.: A novel, competitive mGlu5 receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br J Pharmacol, 2000, 131, 239-244.
13. Dwyer JM, Lepack AE, Duman RS: mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol, 2012, 15, 429-434.
14. Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M et al.: 2-Methyl-6-(phenylethynyl)- pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology, 1999, 38, 1493-1503. (Pubitemid 29457731)
15. Harris BR, Prendergast MA, Gibson DA, Rogers DT, Blanchard JA, Holley RC, Fu MC: Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res, 2002, 26, 1779-1793. (Pubitemid 36008614)
16. Hughes ZA, Neal SJ, Smith DL, Sukoff Rizzo SJ, Pulicicchio CM, Lotarski S, Lu S.: Negative allosteric modulation of metabolic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression. Neuropharmacology, 2012, 66, 202-214.
17. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, Baumann J, Mallinger AG, Zarate CA Jr.: Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Prog Neuropsychopharmacol Biol Psychiatry, 2011, 35, 1155-1159.
18. Iijima M, Fukumoto K, Chaki S: Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test. Behav Brain Res, 2012, 235, 287-292.
19. Koike H, Iijima M, Chaki S: Involvement of the mammalian target of rapamycin signaling in the antidepressant-like effect of group II metabotropic glutamate receptor antagonists. Neuropharmacology, 2011, 61, 1419-1423.
20. Legutko B, Szewczyk B, Pomierny-Chamioo L, Nowak G, Pilc A: Effect of MPEP treatment on brain-derived neurotrophic factor gene expression. Pharmacol Rep, 2006, 58, 427-430. (Pubitemid 44111079)
21. Lenze EJ, Skidmore ER, Begley AE, Newcomer JW, Butters MA, Whyte EM: Memantine for late-life depression and apathy after a disabling medical event: a 12- week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry, 2012, 27, 974-980.
22. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY et al.: mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010, 329, 959-964.
23. Li X, Need AB, Baez M, Witkin JM: Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice. J Pharmacol Exp Ther, 2006, 319, 254-259. (Pubitemid 44455130)
24. Liu RJ, Lee FS, Li XY, Bambico F, Duman RS, Aghajanian GK: Brain-derived neurotrophic factor Val66Met allele impairs basal and ketamine-stimulated synaptogenesis in prefrontal cortex. Biol Psychiatry, 2012, 71, 996-1005.
25. Nakanishi S: Molecular diversity of glutamate receptors and implications for brain function. Science, 1992, 258, 597-603.
26. Paucha A, Brañski P, Szewczyk B, Wieroñska JM, Kak K, Pilc A: Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav, 2005, 81, 901-906. (Pubitemid 41187826)
27. Paucha A, Pilc A: Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther, 2007, 115, 116-147. (Pubitemid 46992810)
28. Paucha-Poniewiera A, Brañski P, Wieroñska JM, Stachowicz K, Sawiñska A, Pilc A: The antidepressantlike action of mGlu5 receptor antagonist, MTEP, in the tail suspension test in mice is serotonin dependent. Psychopharmacology, 2013, doi: 10.1007/s00213-013- 3206-6.
29. Paucha-Poniewiera A, Pilc A: Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test. Prog Neuropsychopharmacol Biol Psychiatry, 2012, 39, 102-106.
30. Pilc A, Kodziñska A, Brañski P, Nowak G, Paucha A, Szewczyk B, Tatarczyñska E: Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology, 2002, 43, 181-187. (Pubitemid 35247606)
31. Pilc A, Wieroñska JM, Skolnick P: Glutamate-based antidepressants: Preclinical Psychopharmacology. Biol Psychiatry, 2013, 73, 1125-113.
32. Pomierny-Chamioo L, Poleszak E, Pilc A, Nowak G: NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep, 2010, 62, 1186-1190.
33. Skolnick P: Antidepressants for the new millennium. Eur J Pharmacol, 1999, 375, 31-40. (Pubitemid 29317590)
34. Szewczyk B, Paucha-Poniewiera A, Poleszak E, Pilc A, Nowak G: Investigational NMDA receptor modulators for depression. Expert Opin Investig Drugs, 2012, 21, 91-102.
35. Tatarczyñska E, Kodziñska A, Chojnacka-Wójcik E, Paucha A, Gasparini F, Kuhn R, Pilc A: Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br J Pharmacol, 2001, 132, 1423-1430. (Pubitemid 32281030)
36. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A et al.: Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron, 1999, 23, 583-592. (Pubitemid 29359928)
37. Wieroñska JM, Szewczyk B, Brañski P, Paucha A, Pilc A: Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids, 2002, 23, 213-216.
38. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, Ruggiero A et al.: Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron, 1998, 21, 707-716. (Pubitemid 28498780)
39. Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK: A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry, 2006, 63, 856-864. (Pubitemid 44188478)
40. Zarate CA Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, Manji HK, Charney DS: A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry, 2006, 163, 153-155. (Pubitemid 43050119)